Adrenocortical carcinoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
== Adrenocortical carcinoma secondary prevention == | |||
*Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | |||
*Surveillance intervals may be increased to 6 months for the next 5 years. | |||
*Surveillance should also include: | |||
**[[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | |||
**The use of [[FDG-PET]] for [[lesions]] of an unclear nature | |||
**Laboratory evaluation for [[steroid hormones]] | |||
**Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 17:16, 3 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma secondary prevention |
|
Risk calculators and risk factors for Adrenocortical carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adrenocortical carcinoma secondary prevention
- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.
- Surveillance intervals may be increased to 6 months for the next 5 years.
- Surveillance should also include: